Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab-adaz
- Development stage
- Approved
- Lead developer
- Sandoz
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Adalimumab-adaz is a tumor necrosis factor (TNF) blocker and a biosimilar to the reference biologic Humira (adalimumab). It is a recombinant human IgG1 monoclonal antibody that binds with high affinity and specificity to soluble and transmembrane TNF-alpha, but not to TNF-beta (lymphotoxin). By neutralizing TNF-alpha, it inhibits the inflammatory cascade and the production of other pro-inflammatory cytokines and adhesion molecules. Originally developed by Sandoz as GP2017, it is commercialized in the United States through a partnership with Cordavis (a CVS Health company). It is approved for the treatment of various autoimmune and inflammatory conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. The product is available in high-concentration, citrate-free formulations designed to reduce injection-site pain.
- Brand names
- HyrimozCordavis Hyrimoz
- Other names
- adalimumab-adaz
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on adalimumab-adaz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab-adaz.